NCT00382733已完成1 期
Oral Topotecan, Utilization for a Metronomic Dosing Schedule to Treat Recurrent or Persistent Solid Tumors
Accelerated Community Oncology Research Network2 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2006年11月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 26
- 试验地点
- 2
- 主要终点
- Maximum Tolerated Dose (MTD) of Single Agent Metronomic Oral Topotecan
研究概览
简要总结
The purpose of this study is to evaluate the effectiveness of oral topotecan and how well the chemotherapy is tolerated (any side effects) when it is given in different dose levels. The study will also collect information on how the medication is being broken down and absorbed in the body and how quality of life is affected during treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient provides written informed consent prior to study-specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.
- •Male or female patients.
- •Patient is at least 18 years of age with recurrent or persistent solid tumors.
- •Patient has adequate hematologic function (absolute neutrophil count [ANC] >= 1500/mL and platelets >= 100,000/mL), adequate renal function (serum creatinine < 2.0 mg/dL; calculated creatinine clearance > 40 mL/min), and adequate hepatic function (serum bilirubin <= 1.5 mg/dL and transaminases <= 3 times the upper limit of normal [3 x ULN]).
- •Patient has Eastern Oncology Cooperative Group (ECOG) performance status of <=
- •Patient has a life expectancy of at least 3 months at time of enrollment.
- •Patient has no medical problems, unrelated to the malignancy, of sufficient severity which would limit full compliance with the study or which would expose him/her to undue risks.
- •Patient has received no more than 2 prior treatment regimens prior to enrollment including chemotherapy, hormonal therapy, biologic therapy, and immunotherapy.
- •Patient has a negative serum or urine pregnancy test within 7 days prior to starting therapy (if a female of childbearing potential).
排除标准
- •Patient is a pregnant or lactating woman. Women of childbearing potential with either a positive or no pregnant test (serum or urine) at baseline. Women of childbearing potential not using a reliable and appropriate contraceptive method will be excluded. (Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential.) Patients must agree to continue contraception for 30 days from the date of the last study drug administration.
- •Patient has serious, uncontrolled, concurrent infection(s).
- •Patient has received whole pelvic or extended field radiation therapy within 4 weeks of enrollment. Patients who have not fully recovered or whose acute toxicity related to prior radiotherapy has not returned to baseline are ineligible.
- •Patient has received myelosuppressive chemotherapy within the last 4 weeks or has not recovered from the myelosuppressive effects of recent chemotherapy.
- •Patient has received another investigational agent within 4 weeks prior to study enrollment.
- •Patient has known hypersensitivity to topoisomerase I inhibitors.
- •Patient is unable to swallow a capsule or has a disease known to affect drug absorption, such as short gut syndrome or active radiation enteritis.
- •Patient has received drugs known to alter absorption such as antacids, proton pump blockers (eg, omeprazole), or H2 receptor antagonists (eg, cimetidine). A washout period of one week (7 days) is required prior to initiating study medication.
结局指标
主要结局
Maximum Tolerated Dose (MTD) of Single Agent Metronomic Oral Topotecan
时间窗: MTD was assessed during the first cycle of treatment (days 1-28).
The MTD of metronomic oral topotecan was determined using a standard 3+3 dose escalation cohort design. The total sample and the number of subjects who receive each dose in this design depends on the frequency of dose limiting toxicities (DLTs)at each dose level. If 0 out of 3 subjects experience a DLT at a given dose level, 3 subjects will be enrolled at the next higher dose level. If greater than or equal to 2 subjects experience a DLT at a given dose level, dose escalation will be stopped. If 1 out of 3 subjects experience a DLT at a given dose level, 3 subjects are enrolled at the same dose level.
次要结局
- Dose Limiting Toxicities (DLT)(DLTs were assessed during the first cycle of treatment (days 1-28).)
- Best Overall Response(Best overall response was assessed after every 8 weeks of treatment and at the end of treatment or time of disease progression, up to 1 year.)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Ph I Oral Topotecan and Temozolomide for Patients With Malignant GliomasGliosarcomaAnaplastic AstrocytomaGlioblastomaNCT00610571Katy Peters62
已完成
2 期
A Pharmacokinetic Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid TumorsSolid TumorsNCT00628732Children's Medical Center Dallas36
已完成
1 期
Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.Multiple MyelomaNCT00325416H. Lee Moffitt Cancer Center and Research Institute177
已完成
2 期
Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung CancerLung CancerNCT00193245SCRI Development Innovations, LLC80
已完成
1 期
Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid TumorsSolid TumorsNCT00502892M.D. Anderson Cancer Center2